Glenmark Pharma cuts worth of COVID-19 drug by 27% to ₹75/pill
Glenmark Prescription drugs had launched FabiFlu final month at a worth of ₹103 per pill
Drug agency Glenmark Prescription drugs on Monday stated it has discount of its antiviral drug Favipiravir, below the model title FabiFlu, for the therapy of sufferers with delicate to average COVID-19, by 27% to ₹75 per pill.
Glenmark Prescription drugs had launched FabiFlu final month at a worth of ₹103 per pill.
In a regulatory submitting Glenmark introduced a worth discount of 27% for FabiFlu. The brand new most retail worth (MRP) is ₹75 per tab, it stated.
“The value discount has been made doable by way of advantages gained from greater yields and higher scale, as each the lively pharmaceutical ingredient (API) and formulations are made at Glenmark’s services in India, the advantages of that are being handed on to sufferers within the nation,” the submitting stated.
“Our inside analysis reveals us that we launched FabiFlu in India on the lowest market price as in comparison with the price of Favipiravir in different international locations the place it’s authorised. And now we hope that this additional worth discount will make it much more accessible for sufferers throughout the nation,” Glenmark Prescription drugs Senior Vice President and Head — India enterprise Alok Malik stated.
Additional, the corporate has commenced a submit advertising and marketing surveillance (PMS) examine on FabiFlu to intently monitor the efficacy and security of the drug in 1,000 sufferers which are prescribed with the oral antiviral, as a part of an open label, multicenter, single arm examine, the submitting added.
“We anticipate this submit advertising and marketing surveillance examine to shed extra mild on the drug’s medical effectiveness and security in a big cohort of sufferers prescribed FabiFlu,” Malik added.
On June 20, Glenmark introduced that it acquired manufacturing and advertising and marketing approval from India’s drug regulator for FabiFlu, making it the primary oral Favipiravir-approved treatment in India for the therapy of delicate to average COVID-19.
Glenmark has additionally accomplished the section three medical trial with Favipiravir (FabiFlu) in delicate to average COVID-19 sufferers in India. The trial outcomes will probably be accessible shortly, the corporate stated.
Glenmark can also be conducting one other section three medical trial to guage the efficacy of two antivirals medicine Favipiravir and Umifenovir as a mix remedy in average hospitalised grownup COVID-19 sufferers in India.
Shares of Glenmark Pharma have been buying and selling 1.34% decrease at ₹421 apiece on BSE.